About ONL Therapeutics
ONL Therapeutics is a private company based in Ann Arbor, Michigan. It has reported $111,494,562 raised in ten offerings on Form D since June 2014. Its chief executive is David Esposito.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Sep 12, 2024 | Sep 16, 2024 | $59,999,998of $65.0M target | 35 | $1.7M | EquityRule 506(b) | Form D ↗ |
| Feb 29, 2024 | Mar 12, 2024 | $9,999,948of $10.0M target | 35 | $285K | EquityRule 506(b) | Form D ↗ |
| Mar 7, 2023 | Mar 15, 2023 | $4,999,956of $15.0M target | 30 | $166K | EquityRule 506(b) | Form D ↗ |
| Dec 18, 2020 | Dec 30, 2020 | $26,802,122of $47.3M target | 44 | $609K | EquityRule 506(b) | Form D ↗ |
| Oct 19, 2020 | Oct 30, 2020 | $2,000,000fully sold | 3 | $666K | OptionsRule 506(b) | Form D ↗ |
| Aug 15, 2019 | Aug 22, 2019 | $3,000,000fully sold | 25 | $120K | Debt, Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Sep 7, 2018 | Sep 21, 2018 | $639,000of $1.0M target | 14 | $45,643 | Debt, Securities on exerciseRule 506(b) | Form D ↗ |
| May 12, 2017 | May 19, 2017 | $2,635,567of $4.3M target | 19 | $138K | EquityRule 506(b) | Form D ↗ |
| Aug 1, 2016 | Aug 10, 2016 | $916,161of $1.2M target | 11 | $83,287 | Debt, Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Jun 17, 2014 | Jun 30, 2014 | $501,810of $1.0M target | 14 | $35,844 | Debt, Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Total, ten offerings | $111,494,562 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on ONL Therapeutics's Form D filed Sep 16, 2024.
Earlier filings also listed Stella Robertson (director, last listed Mar 2024), Mark Hooper (director, last listed Mar 2024), Felicia David-Visser (director, last listed Oct 2020), Christine Gibbons (director, last listed Oct 2020), John Freshley (president and ceo, director, last listed Sep 2018), Rafael Castilla (director, last listed May 2017), William Brinkerhoff (director, last listed Aug 2016) and Loic Couraud (director, last listed Aug 2016).